JPRN-UMIN000010111已完成2 期
Phase 2a trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy. - GBS-01 Phase IIa
ational Cancer Center Hospital East0 个研究点目标入组 47 人开始时间: 2013年3月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 47
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Prior treatment of medicines or supplements extracted from Arctium lappa linne for pancreatic cancer 2)Lactose intolerance 3)Moderate or massive pleural effusion or ascites 4)Symptomatic brain metastasis or a history of brain metastasis 5)Synchronous or asynchronous (within 3 years) other cancer except carcinoma in situ or intramucosal carcinoma. 6)Psychiatric disease 7)Active infection that requires systemic therapy 8)Other serious complications 9)Pregnant females or nursing mothers who can't stop lactation after the recruitment. Patients or partners, who don't attempt to doing contraception during the study period. 10)Patient is judged as inappropriate for study participation by the investigator for any reason.
研究者
相似试验
进行中（未招募）
1 期
ocally Advanced Pancreatic Cancer: Phase II study of cetuximab and 3-D conformal image-guided radiotherapy (PACER Study) - PACER StudyEUCTR2006-001742-13-GBChristie Hospital NHS Trust44
进行中（未招募）
不适用
A trial comparing the current standard treatment (gemcitabine) to the experimental, combined treatments of gemcitabine plus capecitabine.Resectable pancreatic or peri-ampullary cancersMedDRA version: 14.1Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10034446Term: Periampullary carcinoma resectableSystem Organ Class: 100000004864EUCTR2007-004299-38-GBThe University of Liverpool1,396
进行中（未招募）
1 期
Comparing Gemcetabine and Capecitabine versus Gemcitabine monotherapy in chemotherapy for pancreatic cancerResectable pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864EUCTR2007-004299-38-DEThe University of Liverpool1,068
进行中（未招募）
1 期
European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer. - ESPAC-4Resectable pancreatic cancerMedDRA version: 14.1Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864EUCTR2007-004299-38-SEThe University of Liverpool1,080
进行中（未招募）
不适用
European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer. - ESPAC-4Resectable pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableEUCTR2007-004299-38-FIThe University of Liverpool1,080